Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 3Terminated 2Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 58Breast Neoplasms 54Lymphoma 52Multiple Myeloma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Leukemia 48Lymphoma, Non-Hodgkin 46Melanoma 43Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 40Myelodysplastic Syndromes 39Lymphoma, Follicular 29Burkitt Lymphoma 25Hodgkin Disease 24Neoplasm Metastasis 22Recurrence 21Neoplasms 21Lymphoma, Mantle-Cell 20Lymphoma, B-Cell, Marginal Zone 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Ovarian Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Primary Myelofibrosis 14Neoplasms, Plasma Cell 14Myeloproliferative Disorders 14Lymphoma, B-Cell 14Hematologic Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Carcinoma, Renal Cell 13Triple Negative Breast Neoplasms 12

Interventions

Carboplatin 4Sunitinib 3Rituximab 3Pemetrexed 3ponatinib 2pembrolizumab 2osimertinib 2Vincristine 2Prednisone 2Gemcitabine 2Etoposide 2Doxorubicin 2Cyclophosphamide 2ricolinostat 1pralsetinib 1pomalidomide 1nilotinib 1linifanib 1ibritumomab tiuxetan 1emvododstat 1atezolizumab 1Temozolomide 1Taxes 1Sorafenib 1Papanicolaou Test 1Paclitaxel 1Melphalan 1Irinotecan 1Interleukin-2 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms by Histologic Type × Cyclophosphamide × Clear all
NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡